Cholesterol levels classification

Decisions regarding classification and management are based on the LDL cholesterol levels listed in Table 9-3. 

LDL, low-density lipoproteins CHD, coronary heart disease. Classification <130 mg/dL is the desirable LI3L cholesterol level 130-159 mg/dl is borderline-high-risk >160 mg/dl is high-risk. 

TABLE 21—9. Classification of Total and Low-Density Lipoprotein Cholesterol Levels in Children and Adolescents from Families with Hypercholesterolemia or Premature Cardiovascular Disease ... 

Antilipemics lower lipid levels (Table 19.4). Lipids are composed of cholesterol, triglycerides, and phospholipids, which are bound to lipoproteins (Table 19.5) that transport lipids throughout the body. There are three classifications of lipoproteins ... 

Koch et al. determined total cholesterol, phospholipids, and fatty acids in CSF samples from 216 individuals in order to establish the lipid and apo-lipoprotein levels in Cerebrospinal Fluid (CSF) in a large group of individuals, on the basis of which a classification of CSF lipoproteins was made. The cholesterol and phospholipids are measured enzymatically by fluorometric detection of the reaction products. Earlier work had shown reduced levels of cholesterol, phospholipids, and free fatty acids in Cerebrospinal Fluid (CSF) of Alzheimer disease patients. Urine levels of F2-isoprostanes or their major metabolite were not significantly different between Alzheimer s disease patients and controls. In addition, urine and CSF F2-isoprostane levels in Alzheimer s disease patients did not correlate. These results indicate that plasma and urine F2-isoprostanes and F2-neuroprostanes do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of the central nervous system in Alzheimer s disease patients. 

Substance CXI showed a pronounced hypolipidemic effect in patients with hyperlipidemia of Type III, IV and V (Fredrickson classification, see Section 6.2) at an oral daily dose of 300 mg. Patients with hyperlipidemia of Type II responded more slowly and in part higher doses were used. A number of patients in this study were treated with CXI for periods up to 18 months [286]. In another series of cHnical trials it was found that blood levels of cholesterol remained at a reduced level while triglycerides and phosphoHpids returned to their initial values during follow-up period of 2 weeks after the cessation of therapy with 200 mg/day of CXI [287]. 

---